{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:42:08Z","timestamp":1768002128344,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4020-7","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T08:20:01Z","timestamp":1517905201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of the SUCCESS Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-1662","authenticated-orcid":false,"given":"Marianna","family":"Alunni-Fabbroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonie","family":"Majunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth K.","family":"Trapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Tzschaschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W. P.","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Rack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"4","key":"4020_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220\u201341.","journal-title":"CA Cancer J Clin"},{"key":"4020_CR2","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917.","journal-title":"Int J Cancer"},{"key":"4020_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.1991.9.10.1749","volume":"9","author":"RJ Cote","year":"1991","unstructured":"Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991;9:1749\u201356.","journal-title":"J Clin Oncol"},{"key":"4020_CR4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/88.22.1652","volume":"88","author":"IJ Diel","year":"1996","unstructured":"Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4020_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10552-011-9859-8","volume":"23","author":"SY Jung","year":"2012","unstructured":"Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23(1):103\u201312.","journal-title":"Cancer Causes Control"},{"issue":"8","key":"4020_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Peterse JL, van\u2019t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591\u2013602.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4020_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5306\/wjco.v2.i4.171","volume":"2","author":"SV Sree","year":"2011","unstructured":"Sree SV, Ng EY, Acharya RU, Faust O. Breast imaging: a survey. World J Clin Oncol. 2011;2(4):171\u20138.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"4020_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000360438","volume":"9","author":"M Alunni-Fabbroni","year":"2014","unstructured":"Alunni-Fabbroni M, Muller V, Fehm T, Janni W, Rack B. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? Breast Care. 2014;9(1):16\u201321.","journal-title":"Breast Care"},{"key":"4020_CR9","doi-asserted-by":"publisher","unstructured":"Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5). https:\/\/doi.org\/10.1093\/jnci\/dju066 .","DOI":"10.1093\/jnci\/dju066"},{"issue":"7","key":"4020_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23(7):1420\u201330.","journal-title":"J Clin Oncol"},{"issue":"14 Pt 1","key":"4020_CR11","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","volume":"12","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218\u201324.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4020_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","volume":"11","author":"H Schwarzenbach","year":"2014","unstructured":"Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145\u201356.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4020_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13058-015-0645-5","volume":"17","author":"H Schwarzenbach","year":"2015","unstructured":"Schwarzenbach H, Pantel K. Circulating DNA as biomarker in breast cancer. Breast Cancer Res. 2015;17(1):136.","journal-title":"Breast Cancer Res"},{"key":"4020_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fgene.2014.00030","volume":"5","author":"A Turchinovich","year":"2014","unstructured":"Turchinovich A, Cho WC. The origin, function and diagnostic potential of extracellular microRNA in human body fluids. Front Genet. 2014;5:30.","journal-title":"Front Genet"},{"issue":"22","key":"4020_CR15","doi-asserted-by":"publisher","first-page":"6554","DOI":"10.1158\/0008-5472.CAN-13-1841","volume":"73","author":"L Mulrane","year":"2013","unstructured":"Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013;73(22):6554\u201362.","journal-title":"Cancer Res"},{"issue":"Suppl 7","key":"4020_CR16","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1186\/1471-2164-13-S7-S18","volume":"13","author":"HT Chang","year":"2012","unstructured":"Chang HT, Li SC, Ho MR, Pan HW, Ger LP, Hu LY, et al. Comprehensive analysis of microRNAs in breast cancer. BMC Genomics. 2012;13(Suppl 7):S18.","journal-title":"BMC Genomics"},{"key":"4020_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-5876-8-17","volume":"8","author":"K Sasaki","year":"2010","unstructured":"Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, et al. miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med. 2010;8:17.","journal-title":"J Transl Med"},{"issue":"8","key":"4020_CR18","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.biocel.2010.02.002","volume":"42","author":"H Okada","year":"2010","unstructured":"Okada H, Kohanbash G, Lotze MT. MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol. 2010;42(8):1256\u201361.","journal-title":"Int J Biochem Cell Biol"},{"key":"4020_CR19","doi-asserted-by":"crossref","unstructured":"Jasinski-Bergner S, Mandelboim O, Seliger B. The role of microRNAs in the control of innate immune response in cancer. Natl Cancer Inst. 2014;106(10).","DOI":"10.1093\/jnci\/dju257"},{"issue":"1","key":"4020_CR20","doi-asserted-by":"publisher","first-page":"e83113","DOI":"10.1371\/journal.pone.0083113","volume":"9","author":"S Anfossi","year":"2014","unstructured":"Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014;9(1):e83113.","journal-title":"PLoS One"},{"issue":"6","key":"4020_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654\u20139.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"4020_CR22","first-page":"131","volume":"10","author":"J Liu","year":"2013","unstructured":"Liu J, Wu CP, Lu BF, Jiang JT. Mechanism of T cell regulation by microRNAs. Cancer Biol Med. 2013;10(3):131\u20137.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"4020_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4110\/in.2011.11.1.11","volume":"11","author":"TY Ha","year":"2011","unstructured":"Ha TY. The role of MicroRNAs in regulatory T cells and in the immune response. Immune Netw. 2011;11(1):11\u201341.","journal-title":"Immune Netw"},{"issue":"7","key":"4020_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.it.2008.04.004","volume":"29","author":"MA Lindsay","year":"2008","unstructured":"Lindsay MA. microRNAs and the immune response. Trends Immunol. 2008;29(7):343\u201351.","journal-title":"Trends Immunol"},{"issue":"10","key":"4020_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/labinvest.2015.88","volume":"95","author":"J Ma","year":"2015","unstructured":"Ma J, Lin Y, Zhan M, Mann DL, Stass SA, Jiang F. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Lab Invest. 2015;95(10):1197\u2013206.","journal-title":"Lab Invest"},{"issue":"5","key":"4020_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/sj.bjc.6605833","volume":"103","author":"SF Hausler","year":"2010","unstructured":"Hausler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010;103(5):693\u2013700.","journal-title":"Br J Cancer"},{"issue":"3","key":"4020_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/SLA.0b013e3181cc939f","volume":"251","author":"HM Heneghan","year":"2010","unstructured":"Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499\u2013505.","journal-title":"Ann Surg"},{"key":"4020_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fimmu.2015.00019","volume":"6","author":"FJ Sheedy","year":"2015","unstructured":"Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol. 2015;6:19.","journal-title":"Front Immunol"},{"issue":"3","key":"4020_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2005.08.003","volume":"8","author":"JA Schardt","year":"2005","unstructured":"Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. 2005;8(3):227\u201339.","journal-title":"Cancer Cell"},{"issue":"1","key":"4020_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4161\/cc.27027","volume":"13","author":"SJ Song","year":"2014","unstructured":"Song SJ, Pandolfi PP. miR-22 in tumorigenesis. Cell Cycle. 2014;13(1):11\u20132.","journal-title":"Cell Cycle"},{"issue":"11","key":"4020_CR31","doi-asserted-by":"publisher","first-page":"e80266","DOI":"10.1371\/journal.pone.0080266","volume":"8","author":"J Chen","year":"2013","unstructured":"Chen J, Wang M, Guo M, Xie Y, Cong YS. miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One. 2013;8(11):e80266.","journal-title":"PLoS One"},{"key":"4020_CR32","first-page":"401986","volume":"2014","author":"S Wang","year":"2014","unstructured":"Wang S, Li H, Wang J, Wang D, Yao A, Li Q. Prognostic and biological significance of microRNA-127 expression in human breast cancer. Dis Markers. 2014;2014:401986.","journal-title":"Dis Markers"},{"issue":"4","key":"4020_CR33","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1074\/jbc.M608939200","volume":"282","author":"Y Sylvestre","year":"2007","unstructured":"Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, et al. An E2F\/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282(4):2135\u201343.","journal-title":"J Biol Chem"},{"issue":"31","key":"4020_CR34","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/onc.2013.370","volume":"33","author":"X Li","year":"2014","unstructured":"Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene. 2014;33(31):4077\u201388.","journal-title":"Oncogene"},{"issue":"11","key":"4020_CR35","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/jcmm.12353","volume":"18","author":"L Dong","year":"2014","unstructured":"Dong L, Wang X, Tan J, Li H, Qian W, Chen J, et al. Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med. 2014;18(11):2213\u201324.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"4020_CR36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/08830180903093796","volume":"28","author":"E Tili","year":"2009","unstructured":"Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol. 2009;28(5):264\u201384.","journal-title":"Int Rev Immunol"},{"issue":"20","key":"4020_CR37","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical A","year":"2013","unstructured":"World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"17","key":"4020_CR38","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","volume":"20","author":"SE Singletary","year":"2002","unstructured":"Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628\u201336.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4020_CR39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"15","key":"4020_CR40","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","volume":"64","author":"CL Andersen","year":"2004","unstructured":"Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245\u201350.","journal-title":"Cancer Res"},{"issue":"2","key":"4020_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000029984","volume":"19","author":"T Stigbrand","year":"1998","unstructured":"Stigbrand T, Andres C, Bellanger L, Bishr Omary M, Bodenmuller H, Bonfrer H, et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 workshop. Tumour Biol. 1998;19(2):132\u201352.","journal-title":"Tumour Biol"},{"issue":"2","key":"4020_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00404-011-1954-2","volume":"285","author":"B Rack","year":"2012","unstructured":"Rack B, Juckstock J, Gunthner-Biller M, Andergassen U, Neugebauer J, Hepp P, et al. Trastuzumab clears HER2\/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet. 2012;285(2):485\u201392.","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"4020_CR43","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1002\/ijc.27642","volume":"131","author":"NA Healy","year":"2012","unstructured":"Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 2012;131(10):2215\u201322.","journal-title":"Int J Cancer"},{"issue":"30","key":"4020_CR44","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4020_CR45","doi-asserted-by":"publisher","first-page":"101042831769552","DOI":"10.1177\/1010428317695525","volume":"39","author":"ML Gasparri","year":"2017","unstructured":"Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, et al. Beyond circulating microRNA biomarkers: urinary microRNAs in ovarian and breast cancer. Tumour Biol. 2017;39(5):1010428317695525.","journal-title":"Tumour Biol"},{"issue":"17","key":"4020_CR46","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-09-0736","volume":"15","author":"NJ Park","year":"2009","unstructured":"Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15(17):5473\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4020_CR47","first-page":"587","volume":"11","author":"Y Sadakari","year":"2010","unstructured":"Sadakari Y, Ohtsuka T, Ohuchida K, Tsutsumi K, Takahata S, Nakamura M, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP. 2010;11(6):587\u201392.","journal-title":"JOP"},{"key":"4020_CR48","doi-asserted-by":"crossref","unstructured":"Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts. 2017;8(2):61\u201381.","DOI":"10.1515\/bmc-2017-0002"},{"key":"4020_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1600-065X.2008.00602.x","volume":"222","author":"I Marigo","year":"2008","unstructured":"Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162\u201379.","journal-title":"Immunol Rev"},{"issue":"8","key":"4020_CR50","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/ijc.23717","volume":"123","author":"W He","year":"2008","unstructured":"He W, Kularatne SA, Kalli KR, Prendergast FG, Amato RJ, Klee GG, et al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008;123(8):1968\u201373.","journal-title":"Int J Cancer"},{"issue":"1","key":"4020_CR51","doi-asserted-by":"publisher","first-page":"e53141","DOI":"10.1371\/journal.pone.0053141","volume":"8","author":"EK Ng","year":"2013","unstructured":"Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8(1):e53141.","journal-title":"PLoS One"},{"issue":"25","key":"4020_CR52","doi-asserted-by":"publisher","first-page":"9965","DOI":"10.1073\/pnas.1207327109","volume":"109","author":"T Wu","year":"2012","unstructured":"Wu T, Wieland A, Araki K, Davis CW, Ye L, Hale JS, et al. Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A. 2012;109(25):9965\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4020_CR53","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1084\/jem.20091299","volume":"207","author":"C Duy","year":"2010","unstructured":"Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010;207(6):1209\u201321.","journal-title":"J Exp Med"},{"issue":"21","key":"4020_CR54","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1158\/1078-0432.CCR-12-1407","volume":"18","author":"D Madhavan","year":"2012","unstructured":"Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 2012;18(21):5972\u201382.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4020_CR55","doi-asserted-by":"publisher","first-page":"e101950","DOI":"10.1371\/journal.pone.0101950","volume":"9","author":"AR Kodahl","year":"2014","unstructured":"Kodahl AR, Zeuthen P, Binder H, Knoop AS, Ditzel HJ. Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women. PLoS One. 2014;9(7):e101950.","journal-title":"PLoS One"},{"key":"4020_CR56","doi-asserted-by":"crossref","unstructured":"Atarod S, Smith H, Dickinson A, Wang XN. MicroRNA levels quantified in whole blood varies from PBMCs. F1000Research. 2014;3:183.","DOI":"10.12688\/f1000research.4884.3"},{"issue":"1","key":"4020_CR57","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-016-2454-3","volume":"16","author":"J Jueckstock","year":"2016","unstructured":"Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, et al. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - results of the German SUCCESS-A- trial. BMC Cancer. 2016;16(1):401.","journal-title":"BMC Cancer"},{"issue":"7163","key":"4020_CR58","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature06174","volume":"449","author":"L Ma","year":"2007","unstructured":"Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682\u20138.","journal-title":"Nature"},{"issue":"24","key":"4020_CR59","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1101\/gad.1872909","volume":"23","author":"P Mu","year":"2009","unstructured":"Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23(24):2806\u201311.","journal-title":"Genes Dev"},{"issue":"24","key":"4020_CR60","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1101\/gad.1861409","volume":"23","author":"V Olive","year":"2009","unstructured":"Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839\u201349.","journal-title":"Genes Dev"},{"issue":"1-3","key":"4020_CR61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12026-010-8196-4","volume":"49","author":"EA Lykken","year":"2011","unstructured":"Lykken EA, Li QJ. microRNAs at the regulatory frontier: an investigation into how microRNAs impact the development and effector functions of CD4 T cells. Immunol Res. 2011;49(1-3):87\u201396.","journal-title":"Immunol Res"},{"issue":"11","key":"4020_CR62","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1261\/rna.1034808","volume":"14","author":"LX Yan","year":"2008","unstructured":"Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348\u201360.","journal-title":"RNA"},{"issue":"19","key":"4020_CR63","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1038\/sj.onc.1210083","volume":"26","author":"ML Si","year":"2007","unstructured":"Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799\u2013803.","journal-title":"Oncogene"},{"issue":"2","key":"4020_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.02.004","volume":"59","author":"L Wang","year":"2014","unstructured":"Wang L, He L, Zhang R, Liu X, Ren Y, Liu Z, et al. Regulation of T lymphocyte activation by microRNA-21. Mol Immunol. 2014;59(2):163\u201371.","journal-title":"Mol Immunol"},{"issue":"13","key":"4020_CR65","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1128\/MCB.01875-08","volume":"29","author":"DP Pandey","year":"2009","unstructured":"Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol. 2009;29(13):3783\u201390.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"4020_CR66","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ncb1722","volume":"10","author":"PA Gregory","year":"2008","unstructured":"Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593\u2013601.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"4020_CR67","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1101\/gad.1640608","volume":"22","author":"SM Park","year":"2008","unstructured":"Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894\u2013907.","journal-title":"Genes Dev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T13:46:13Z","timestamp":1603806373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4020"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4020-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"2 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by all the involved ethical boards (lead ethical board: Ludwig-Maximilians-University Munich) and conducted in accordance with the Declaration of Helsinki. All patients and healthy donors provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In frame of the SUCCESS A clinical trial, BR, WJ, AS, PAF received research funding and\/or speaker honoraria from AstraZeneca, Chugai, Lilly, Novartis, Sanofi-Aventis and Janssen Diagnostics. MA-F, TB, RL, TF, TWPF, LM, SM, EKT and MT have no competing interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"141"}}